Patient characteristics
| Pt . | Subtype . | Karyotype . | Age at diagnosis, y . | Sex . | MRD level at day 29 . | MRD level at week 14 . | MRD risk∗ . |
|---|---|---|---|---|---|---|---|
| 1 | Pre B | t(12;21) | 12 | F | N/A | N/A | Low |
| 2 | Pre B | Hyperdiploid | 3 | F | <0.01% | N/A | Low |
| 3 | Pre B | Hyperdiploid | 1 | F | <0.01% | N/A | Low |
| 4 | Pre B | t(9;14), −20,+21, +3mar | 2 | F | <0.01% | N/A | Low |
| 5 | Pre B | t(12;21) | 6 | M | N/A | N/A | Low |
| 6 | Pre B | 46xx | 17 | F | <0.01% | N/A | Low |
| 7 | Pre B | t(8;11),+1,+7,+9,+12,+21,–3,–14 | 3 | M | <0.01% | <0.01% | Int |
| 8 | Pre B | iAMP21 | 11 | M | <0.01% | <0.01% | Int |
| 9 | Pro B | KMT2A rearr | 17 | F | <0.01% | <0.01% | Int |
| 10 | Pre B | t(12;21),–10,+12,–13,+21,+3mar | 5 | M | 0.14% | N/A | Int |
| 11 | c-ALL | t(9;22) | 5 | M | N/A | N/A | Int |
| 12 | Pre B | 46xx | 16 | F | 0.24% | <0.01% | Int |
| 13 | Pre B | der21, +21 | 11 | F | 0.01% | N/A | Int |
| 14 | Pre B | 46xy | 15 | M | N/A | N/A | Int |
| 15 | Pre B | PDGFRB rearr, −12p | 8 | F | 19.0% | <0.01% | Int |
| 16 | Pre B | t(1;12),+1,der12,+12,+mar | 4 | M | N/A | N/A | Low |
| 17 | Pre B | t(1;19) | 12 | M | N/A | N/A | Low |
| 18 | Pre B | t(1;19) | 15 | F | N/A | N/A | Low |
| 19 | Pre B | t(1;19) | 12 | M | <0.05% | N/A | Low |
| 20 | T-ALL | −6 | 13 | M | 0.03% | <0.01% | Int |
| 21 | T-ALL | der11,+7 | 8 | F | 18.0% | N/A | High |
| 22 | T-ALL | +ABL1 | 10 | M | <0.01% | N/A | Int |
| 23 | T-ALL | 46xy | 13 | M | N/A | N/A | High |
| 24 | T-ALL | RUNX1 rearr | 3 | M | N/A | N/A | ND |
| 25 | T-ALL | t(8;14),–9,i9 | 3 | M | <0.01% | N/A | Low |
| 26 | T-ALL | −4, −9 | 9 | M | <0.01% | N/A | Low |
| 27 | T-ALL | 46xy | 6 | M | 0.06% | <0.01% | Low |
| 28 | T-ALL | t(11;14) | 4 | M | <0.01% | N/A | Low |
| 29 | T-ALL | ND | 13 | M | <0.01% | N/A | Low |
| Pt . | Subtype . | Karyotype . | Age at diagnosis, y . | Sex . | MRD level at day 29 . | MRD level at week 14 . | MRD risk∗ . |
|---|---|---|---|---|---|---|---|
| 1 | Pre B | t(12;21) | 12 | F | N/A | N/A | Low |
| 2 | Pre B | Hyperdiploid | 3 | F | <0.01% | N/A | Low |
| 3 | Pre B | Hyperdiploid | 1 | F | <0.01% | N/A | Low |
| 4 | Pre B | t(9;14), −20,+21, +3mar | 2 | F | <0.01% | N/A | Low |
| 5 | Pre B | t(12;21) | 6 | M | N/A | N/A | Low |
| 6 | Pre B | 46xx | 17 | F | <0.01% | N/A | Low |
| 7 | Pre B | t(8;11),+1,+7,+9,+12,+21,–3,–14 | 3 | M | <0.01% | <0.01% | Int |
| 8 | Pre B | iAMP21 | 11 | M | <0.01% | <0.01% | Int |
| 9 | Pro B | KMT2A rearr | 17 | F | <0.01% | <0.01% | Int |
| 10 | Pre B | t(12;21),–10,+12,–13,+21,+3mar | 5 | M | 0.14% | N/A | Int |
| 11 | c-ALL | t(9;22) | 5 | M | N/A | N/A | Int |
| 12 | Pre B | 46xx | 16 | F | 0.24% | <0.01% | Int |
| 13 | Pre B | der21, +21 | 11 | F | 0.01% | N/A | Int |
| 14 | Pre B | 46xy | 15 | M | N/A | N/A | Int |
| 15 | Pre B | PDGFRB rearr, −12p | 8 | F | 19.0% | <0.01% | Int |
| 16 | Pre B | t(1;12),+1,der12,+12,+mar | 4 | M | N/A | N/A | Low |
| 17 | Pre B | t(1;19) | 12 | M | N/A | N/A | Low |
| 18 | Pre B | t(1;19) | 15 | F | N/A | N/A | Low |
| 19 | Pre B | t(1;19) | 12 | M | <0.05% | N/A | Low |
| 20 | T-ALL | −6 | 13 | M | 0.03% | <0.01% | Int |
| 21 | T-ALL | der11,+7 | 8 | F | 18.0% | N/A | High |
| 22 | T-ALL | +ABL1 | 10 | M | <0.01% | N/A | Int |
| 23 | T-ALL | 46xy | 13 | M | N/A | N/A | High |
| 24 | T-ALL | RUNX1 rearr | 3 | M | N/A | N/A | ND |
| 25 | T-ALL | t(8;14),–9,i9 | 3 | M | <0.01% | N/A | Low |
| 26 | T-ALL | −4, −9 | 9 | M | <0.01% | N/A | Low |
| 27 | T-ALL | 46xy | 6 | M | 0.06% | <0.01% | Low |
| 28 | T-ALL | t(11;14) | 4 | M | <0.01% | N/A | Low |
| 29 | T-ALL | ND | 13 | M | <0.01% | N/A | Low |
F, female; Int, intermediate; M, male; N/A, not available; ND, not determined.
MRD risk status at day 29 for Pt 23 (UKALL 2003 protocol) and at day 29 or week 14 for all other patients (UKALL 2011).